| Biomarker ID | 1039 |
| PMID | 23322201 |
| Year | 2013 |
| Biomarker | Alanyl membrane aminopeptidase (ANPEP) |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Renin-angiotensin system, SARS coronavirus protease, Dendritic cells in regulating TH1 and TH2 development, Glutathione metabolism, C-Myb transcription factor network |
| Experiment | Prostate Cancer Vs Non Malignant Tissue |
| Type of Biomarker | Diagnostic |
| Cohort | 248 Non Malignant and PCa tissue samples were used for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0025 |
| Method Used | quantitative methylation-specific PCR assay |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |